Introduction
============

The prevalence of atrial fibrillation (AF) and its associated mortality and morbidity are expected to double or triple within the next two to three decades, driven by population ageing and increased incidence of AF.[@ehz782-B1]^,^[@ehz782-B2] Even on optimal anticoagulation and rate control therapy, patients with AF are at high risk of cardiovascular death, particularly sudden death and death due to heart failure.[@ehz782-B3]^,^[@ehz782-B4] Rhythm control therapy using antiarrhythmic drugs, cardioversion, and AF ablation, is clinically used to improve AF-related symptoms.[@ehz782-B5] Currently, there is no established indication for rhythm control therapy apart from improvement of AF-related symptoms.[@ehz782-B6] The CABANA (Catheter Ablation vs. Anti-arrhythmic Drug Therapy for Atrial Fibrillation) trial recently provided new confirmation on the safety of AF ablation in contemporary AF patients at risk of stroke.[@ehz782-B9] The smaller CASTLE-AF (Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation) suggests that AF ablation could improve outcomes in patients with AF and severe heart failure compared to drug therapy, combining rate control therapy and antiarrhythmic drug therapy.[@ehz782-B10] Here, we review the available evidence supporting the use of rhythm control therapy in patients with AF, discuss potential implications for indications, and highlight clinical evidence gaps.

Rhythm control therapy improves atrial fibrillation-related symptoms
====================================================================

Restoring and maintaining sinus rhythm indicated to minimize symptoms is a main goal in patients who remain symptomatic despite adequate rate control.[@ehz782-B11]^,^[@ehz782-B12] Interestingly, the effects of rhythm control on quality of life are less uniform than their clear effects on maintaining sinus rhythm (*Table [1](#ehz782-T1){ref-type="table"}*). Both natural variation in patient-reported quality of life, imprecise instruments to assess quality of life, and variable effects of rhythm control therapy on quality of life in individual patients can explain this heterogeneity.[@ehz782-B13]^,^[@ehz782-B14] The European Heart Rhythm Association (EHRA) symptom score was introduced in 2007 as a simple clinical tool to quantify AF-related symptoms,[@ehz782-B15] with subsequent refinement and validation.[@ehz782-B16] Several disease-specific instruments are available, all with specific strengths and limitations.[@ehz782-B17] In addition, perceived AF-related symptoms may not always be due to AF, and concomitant cardiovascular diseases and risk factors may affect patient's health perception in addition to the arrhythmia itself.[@ehz782-B18]^,^[@ehz782-B19] Furthermore, patients with paroxysmal AF can be expected to report variable quality of life depending on their rhythm at the time of assessment, on their ability to memorize past symptoms during clusters of AF episodes, and by anxiety related to future episodes of AF.

###### 

Effects of rhythm control therapy using antiarrhythmic drugs in controlled clinical trials

                                       PIAF                                              CTAF                                                      RACE                                                                          AFFIRM                                                                                                                                STAF                                                             SAFE-T                                                           AF-CHF                                                                                                 ATHENA                                                                                Flec-SL
  ------------------------------------ ------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ------------------------------------------------
  Year of publication                  2000                                              2000                                                      2002                                                                          2002                                                                                                                                  2003                                                             2005                                                             2008                                                                                                   2009                                                                                  2012
  Number of patients                   252                                               403                                                       522                                                                           4060                                                                                                                                  200                                                              665                                                              1376                                                                                                   4628                                                                                  635
  Mean age                             60                                                65                                                        68                                                                            70                                                                                                                                    66                                                               67                                                               67                                                                                                     72                                                                                    64
  Sex                                  73% male                                          56% male                                                  64% male                                                                      61% male                                                                                                                              64% male                                                         99% male                                                         81% male                                                                                               53% male                                                                              66% male
  Inclusion criteria                   Symptomatic persistent AF \<1 year duration       Symptomatic AF eligible for antiarrhythmic drug therapy   Recurrent persistent AF \<1 year duration                                     \>65 years or \<65 years with additional risk factor for stroke with AF likely to be recurrent and likely to cause illness or death   Persistent AF either \>4 weeks or enlarged LA or heart failure   Persistent AF on anticoagulation                                 Symptomatic HF (NYHA II--IV), LVEF \<36%                                                               Patients with AF, and \>70 years with one comorbidity or \>75 years                   Patients undergoing planned cardioversion
  Exclusion criteria                   NYHA IV, unstable angina                          NYHA III--IV, severe CKD, QTc \>0.48                      NYHA IV, previous amiodarone, pacemaker                                       Reversible cause of AF                                                                                                                Permanent AF \>2 years, paroxysmal AF                            NYHA III--IV, CKD, initially AF \>12 months (eliminated later)   AV block, recent decompensation, dialysis                                                              Permanent AF, NYHA IV or unstable HF, bradycardia, AV block                           Unsuitable for flecainide
  AF pattern                           Persistent AF                                     50% persistent                                            Persistent AF                                                                 69% AF episode longer than 2 days                                                                                                     Persistent AF                                                    Persistent AF                                                    2/3 persistent                                                                                         Not available but 25% were in AF at time of randomization                             Persistent AF
  Duration of AF at baseline (years)   0.3 (0.3)                                         \<0.5                                                     0.9                                                                           35% first episode of AF                                                                                                               0.5 (0.2)                                                        74% \< 1                                                         \<1                                                                                                    Not available                                                                         2.3
  Rhythm control intervention          Amiodarone                                        Amiodarone                                                Antiarrhythmic drugs                                                          Antiarrhythmic drugs                                                                                                                  Antiarrhythmic drugs                                             Sotalol, amiodarone                                              Amiodarone                                                                                             Dronedarone                                                                           Flecainide (short and long term)
  Comparator therapy                   Rate control (diltiazem)                          Sotalol or propafenone                                    Rate control                                                                  Rate control                                                                                                                          Rate control                                                     Placebo                                                          Rate control                                                                                           Placebo                                                                               No antiarrhythmic drug
  Primary endpoint                     Recurrent AF                                      Recurrent AF                                              Cardiovascular death, HF, stroke, bleeding, pacemaker, or SAE                 Death                                                                                                                                 MACCE                                                            Recurrent AF                                                     Cardiovascular death                                                                                   Cardiovascular hospitalization or death                                               Recurrent AF
  Method for detecting recurrent AF    24-h Holter every 3 months                        Regular ECG during follow-up                              Regular ECG during follow-up                                                  Not specified                                                                                                                         Regular ECG upon follow-up                                       Monthly ECG                                                      Yearly ECG                                                                                             Yearly ECG                                                                            Daily telemetric ECG
  Sinus rhythm maintenance             56% at 52 weeks on amiodarone, 10% on diltiazem   40% at 2 years on sotalol/prop, 60% on amiodarone         38% in rhythm control group, 10% in rate control during 2.3 years follow-up   60% in active group, 30% in control group at 5 years                                                                                  40% at 12 months, 26% at 24 months in active group               At 12 months: 52% amio, 32% sotalol, 13% placebo                 At 48 month visit: 70% (amio) vs. 30% (control), 58% of rhythm control group had AF during follow-up   Median time to first AF recurrence 737 days in dronedarone group and 498 in placebo   60% (flecainide) vs. 40% (control) at 6 months
  Outcomes                             Improved 6MWT in rhythm control patients          No difference in QoL between groups                       No difference in mortality or QoL between groups                              No difference in mortality or QoL between groups                                                                                      No difference in MACCE. Reduced recurrent AF                     No difference in mortality or QoL between groups                 No difference in mortality or QoL between groups                                                       Lower mortality and less hospitalizations in patients randomized to dronedarone       Improved quality of life in all groups

All studies found reduced AF recurrences in patients randomized to rhythm control therapy. Several studies reported improved quality of life in patients with successful sinus rhythm maintenance, e.g. in SAFE-T and AF-CHF. AAD antiarrhythmic drug. 6MWT, six minute walking test; QoL, quality of life.

Effectiveness and safety of rhythm control therapy
==================================================

The success of rhythm control therapy depends on multiple factors including the number, type, and severity of underlying conditions, age, gender, adherence to antiarrhythmic drug therapy, and factors related to the quality of the AF ablation procedure.[@ehz782-B2]^,^[@ehz782-B8]^,^[@ehz782-B20] Furthermore, AF recurrence rates depend on the intensity of electrocardiogram (ECG) monitoring and duration of follow-up.[@ehz782-B15] Thus, comparing absolute recurrence rates between studies and comparisons to historical controls can be misleading (*Table [1](#ehz782-T1){ref-type="table"}*).

Effectiveness and safety of antiarrhythmic drug therapy
=======================================================

On average, antiarrhythmic drugs double the proportion of patients who maintain sinus rhythm. Amiodarone is more effective than other antiarrhythmic drugs in maintaining sinus rhythm, and catheter ablation is more effective than antiarrhythmic drugs.[@ehz782-B8] The long-term complication rates of antiarrhythmic drug therapy are comparable to complications in patients treated with AF ablation.[@ehz782-B9]^,^[@ehz782-B21] Although amiodarone has been associated with adverse outcomes in non-randomized analyses of patients at very high risk,[@ehz782-B22] the safety of antiarrhythmic drug therapy found in recent randomized trials in patients with AF attenuates historical safety concerns,[@ehz782-B9]^,^[@ehz782-B21] particularly in patients with heart failure.[@ehz782-B23] Unlike earlier trials of antiarrhythmic drugs compared to placebo or rate control therapy (*Table [1](#ehz782-T1){ref-type="table"}*),[@ehz782-B23] antiarrhythmic drug therapy with dronedarone was associated with reduced cardiovascular hospitalizations and cardiovascular deaths compared to placebo.[@ehz782-B26] The same substance, dronedarone, used as a rate-controlling agent, was associated with higher rates of heart failure, stroke, and cardiovascular death in patients with permanent AF in the PALLAS trial.[@ehz782-B27] Patients included in PALLAS were not considered suitable for rhythm control therapy, did not receive interventions to restore sinus rhythm (e.g. cardioversion, AF ablation) and had severe heart failure. Hence, they were deprived of any potential to benefit of sinus rhythm. Patients treated with dronedarone in ATHENA, in contrast, received that therapy to restore sinus rhythm. Taken together, these data may suggest that the beneficial effects found in ATHENA could be associated with its rhythm controlling effect, but more data are needed.

Antiarrhythmic drugs are also effective after AF ablation. Two recent randomized studies (AMIO-CAT[@ehz782-B28] and POWDER-AF[@ehz782-B29]) showed that adding antiarrhythmic drug therapy to AF ablation improves sinus rhythm maintenance for the duration of therapy. This synergistic effect of antiarrhythmic drugs with AF ablation reflects the common (approximately 50% of patients) use of antiarrhythmic drugs 1 year after AF ablation.[@ehz782-B30] A substudy within AMIO-CAT measuring brain natriuretic peptide suggested that biomarkers may improve identification of patients at risk for recurrent AF,[@ehz782-B31] pointing potentially towards personalized or stratified selection of patients for specific rhythm control therapies.[@ehz782-B32]

Effectiveness and safety of atrial fibrillation ablation
========================================================

Initially evaluated in young patients with highly symptomatic AF (mean age around 55 years) who were refractory to antiarrhythmic drug therapy, AF ablation maintains sinus rhythm better than antiarrhythmic drugs.[@ehz782-B33]^,^[@ehz782-B34] This was confirmed in CABANA.[@ehz782-B9] A meta-analysis of randomized trials (6167 patients) found that AF ablation achieves freedom from recurrent AF in approximately half of the patients \[53% (46--60), mean (95% confidence interval, CI)\], with slightly higher recurrence rates in patients with chronic forms of AF.[@ehz782-B35] Periprocedural complications occur in ca. 5% of patients (7.8% in EORP AF ablation, 4.8% in CABANA), including tamponade (ca. 1%), stroke, or transient ischaemic attack (ca. 0.5--1% in anticoagulated patients), access site complications (ca. 2--3%), and death (\<1%).[@ehz782-B30]^,^[@ehz782-B36] Reablation is performed in 20--50% of patients undergoing a first AF ablation. During long-term follow-up for up to 10 years, up to 60% of AF ablation patients remain free of clinically relevant recurrences of AF (with around three-fourths in sinus rhythm after 1 year), and approximately half of these patients receive combination therapy with antiarrhythmic drugs.[@ehz782-B39] Whether additional ablation strategies improve these outcomes needs to be investigated.[@ehz782-B42]

Atrial fibrillation ablation compared to antiarrhythmic drug therapy after CABANA
=================================================================================

CABANA was designed to test whether AF ablation can reduce mortality compared to antiarrhythmic drugs in patients with AF in need for rhythm control therapy and with stroke risk factors.[@ehz782-B43] In early 2013, a planned, blind data review identified slow enrolment and lower event rates than anticipated. This resulted in a change in primary endpoint from all-cause mortality to a composite of death, disabling stroke, serious bleeding, or cardiac arrest. In addition, the sample size was reduced. The results have just been reported[@ehz782-B9]: Of the 2204 patients randomized (median age, 68 years; 37% female; 57% persistent AF), 89.3% completed the trial. In patients randomized to AF ablation, 91% underwent the procedure, while AF ablation was performed in 27.5% of the patients randomized to drug therapy, in line with expectations at the start of the trial.[@ehz782-B43] Safety of rhythm control therapy was good in this elderly patient population (mean age 68 years), with low complication rates in both arms: Patients randomized to AF ablation experienced tamponade (0.8%), haematomas (2.3%), and pseudoaneurysms (1.1%). Patients randomized to antiarrhythmic drug therapy experienced thyroid disorders (1.6%) and proarrhythmia (0.8%). The primary outcome was not different between groups.[@ehz782-B9] Over a median follow-up of 48.5 months, the primary endpoint occurred in 8.0% of patients randomized to AF ablation, and in 9.2% of patients randomized to antiarrhythmic drug therapy \[hazard ratio (HR) 0.86, 95% CI 0.65--1.15; *P* = 0.30\]. Key secondary outcomes were not different between random groups, including all-cause mortality was 5.2% and 6.1% (HR 0.85, 95% CI 0.60--1.21; *P* = 0.38), death or cardiovascular hospitalization rates were 51.7% and 58.1% for (HR 0.83, 95% CI 0.74--0.93; *P* = 0.001). Recurrent AF was less common in patients randomized to AF ablation in the subgroup of 1240 patients undergoing systematic ECG monitoring (HR 0.52, 95% CI 0.45--0.60; *P* \< 0.001). Both treatment groups showed improved quality of life, as assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary score and the Mayo AF-Specific Symptom Inventory (MAFSI). Patients randomized to catheter ablation showed a greater improvement in quality of life (mean difference of 5.3 points).[@ehz782-B44] This greater effect of AF ablation on quality of life is consistent with the main finding of the Swedish CAPTAF trial.[@ehz782-B45]

Similar to other observational data sets, on-treatment analysis suggested improved outcomes in patients undergoing AF ablation. These findings are additionally supported by a recent study using a large US administrative database of routine patient data, analysing patients who meet the CABANA inclusion criteria.[@ehz782-B46] Unknown and known confounders, censoring of events---either intentionally by study design or unintentionally because of loss to follow-up---, self-selection of low risk patients to cross over to ablation, and immortal time bias are some of the sources of bias that can explain these findings.[@ehz782-B47]

Rhythm control therapy in patients with atrial fibrillation and heart failure
=============================================================================

Atrial fibrillation and heart failure (AF+HF) frequently coexist and this is associated with high morbidity and mortality.[@ehz782-B48] To improve outcomes, restoring and maintaining sinus rhythm has been proposed in patients with AF+HF. Amiodarone is the only antiarrhythmic drug with sufficient safety data in patients with reduced left ventricular ejection fraction.[@ehz782-B8] Large randomized trials of antiarrhythmic drugs compared to rate control in patients with AF+HF did not find differences in all-cause mortality, cardiovascular mortality, or heart failure hospitalizations.[@ehz782-B23]^,^[@ehz782-B49]^,^[@ehz782-B50] Likewise, patients who maintain sinus rhythm ('successful rhythm control therapy') did not have better survival than those with recurrent AF.[@ehz782-B50] Several small case series and controlled trials found that patients undergoing AF ablation have improved left ventricular function, often using echocardiography to assess left ventricular (LV) function (*Table [2](#ehz782-T2){ref-type="table"}*): four out of five relatively small studies found improved left ventricular function in patients with AF+HF randomized to AF ablation (*Table [2](#ehz782-T2){ref-type="table"}*),[@ehz782-B51] largely seen in trials that assessed left ventricular function by echocardiography, which is less reliable in AF than in sinus rhythm.[@ehz782-B60] There were associated improvements in exercise capacity and brain natriuretic peptide (BNP) levels (*[Take home figure](#ehz782-F1){ref-type="fig"}*, bottom panel). Improved exercise capacity and to some extent improved left ventricular function, but not lower BNP, could be partially explained by bias in unblinded trials. These effects have been extrapolated with a certain enthusiasm.[@ehz782-B61] The largest trial comparing AF ablation with 'medical therapy' (mostly rate control, but including antiarrhythmic drugs) in patients with AF+HF is CASTLE-AF (*Table [2](#ehz782-T2){ref-type="table"}*).[@ehz782-B10] The quality of rate control therapy may have affected changes in LV function in the control group of the published trials that used rate control as comparator. Thirty-four of the 363 randomized patients were lost to follow-up despite an implanted device allowing home monitoring. In the remaining patients, catheter ablation reduced mortality and HF hospitalizations (28.5% compared with 45%), but had no effect on all-cause hospitalizations and stroke. Details of the drug therapy given to patients randomized to 'medical therapy' have not been published. One-third of the patients assigned to medical therapy were on antiarrhythmic drugs at their final follow-up, 22% were in sinus rhythm at 60 months (compared to 63% in the AF ablation arm, *Table [2](#ehz782-T2){ref-type="table"}*). In line with these findings, the recent update of the AHA/ACC/HRS guidelines for AF included a Class IIb recommendation for AF ablation in patients with heart failure. So far, there is no information about outcomes following catheter ablation for AF in patients with heart failure and a preserved ejection fraction. Despite these limitations, CASTLE-AF and the AATAC trial[@ehz782-B62] contribute evidence that selected patients with AF+HF benefit from AF ablation (*Table [2](#ehz782-T2){ref-type="table"}*),[@ehz782-B51] but open questions remain regarding selection of adequate patients and validity of the findings in 'all-comer' patients. More research is needed to determine the effect of AF ablation on cardiovascular outcomes in patients with AF+HF.

![AF ablation may affect cardiovascular outcomes (top panel) and appears to improve left ventricular function (bottom panel) in selected patients with Atrial Fibrillation and Heart Failure. Further evidence is needed to underpin these hypothesis-generating findings.](ehz782f1){#ehz782-F1}

###### 

Randomized studies comparing pharmacological rate or rhythm control, or, in PABA-CHF, AV nodal ablation and biventricular pacing, with catheter ablation in patients with AF and systolic dysfunction with reduced ejection fraction

                                                 PABA-CHF                                                               MacDonald                                                                                   ARC-AF                                                                      CAMTAF                                                                                                       AATAC                                                                                                                                  CAMERA-MRI                                                                      CASTLE-AF
  ---------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Year of publication                            2008                                                                   2011                                                                                        2013                                                                        2014                                                                                                         2016                                                                                                                                   2017                                                                            2018
  Number of patients                             81                                                                     41                                                                                          52                                                                          50                                                                                                           203                                                                                                                                    66                                                                              363[^a^](#tblfn2){ref-type="table-fn"}
  Age                                            61                                                                     63                                                                                          63                                                                          58                                                                                                           61                                                                                                                                     61                                                                              64
  Sex                                            \>80% male                                                             78% male                                                                                    \>80% male                                                                  96% male                                                                                                     74% male                                                                                                                               91% male                                                                        86% male
  Type of patients                               NYHA II--III, LVEF \<40%                                               NYHA II--IV, LVEF \<35%                                                                     NYHA II--IV, LVEF \<35%                                                     NYHA II--IV, LVEF \<50%                                                                                      NYHA II--III, LVEF \<40%, dual-chamber ICD or CRT                                                                                      NYHA II--IV, LVEF \<45%[^b^](#tblfn3){ref-type="table-fn"}                      NYHA II--IV, LVEF \<35%, dual-chamber ICD or CRT
  Exclusion criteria                             Post-operative AF, reversible causes of AF or HF, prior AF ablation    Paroxysmal AF, QRS duration \>150 ms, myocarditis                                           Reversible causes of AF and HF                                              Previous AF ablation, reversible HF cause                                                                    Amiodraone therapy, AF \<3 months duration, reversible AF                                                                              Paroxysmal AF, contraindications to ablation or MRI, ischaemic cardiomyopathy   Prior AF ablation, LA diameter \>60 mm
  Proportion with ischaemic HF aetiology         70%                                                                    49%                                                                                         33%                                                                         26%                                                                                                          64%                                                                                                                                    0%                                                                              46%
  AF pattern                                     52% paroxysmal                                                         100% chronic                                                                                100% chronic                                                                100% chronic                                                                                                 100% chronic                                                                                                                           100% chronic                                                                    33% paroxysmal
  Duration of AF at baseline                     48 months                                                              44 months                                                                                   51 months                                                                   24 months                                                                                                    9 months                                                                                                                               22 months                                                                       Not known
  Comparator therapy                             Rate control (AV nodal ablation + biventricular ICD)                   Pharmacological rate control                                                                Pharmacological rate control                                                Pharmacological rate control                                                                                 Rhythm control with amiodarone                                                                                                         Pharmacological rate control                                                    Mixture of rate control and rhythm control
  Primary endpoint                               Composite of LVEF, 6MWT distance, and MLHFQ score                      Change in LVEF from randomization to last study visit                                       Peak VO~2~                                                                  LVEF at 6 months                                                                                             Freedom from AF, AFL, or AT of \>30 s duration off AAD at follow-up                                                                    Change in LVEF from baseline at 6 months on cardiac MRI                         Composite of all-cause mortality or worsening of HF requiring unplanned hospitalization
  Method for AF recurrence assessment            External loop recorder (AF ablation patients only)                     24-h Holter at baseline, 3 and 6 months                                                     48-h Holter at 6 and 12 months                                              48-h Holter at 1, 3, and 6 months (and 12 months in AF ablation patients)                                    Device interrogation at 3, 6 12, and 24 months                                                                                         Implanted loop recorder in AF ablation patients                                 Device interrogation at 3, 6, 12, 24, 36, 48, and 60 months
  Sinus rhythm maintenance at end of follow-up   88%                                                                    50%                                                                                         88%                                                                         73%                                                                                                          70%                                                                                                                                    75% (56% without antiarrhythmic drugs)                                          63%
  Outcomes                                       Improved LVEF, 6MWT distance and QoL (MLHFQ) in AF ablation patients   No difference in LV or RV function (measured by cardiac MRI), 6MWT, or BNP between groups   Improved exercise performance, QoL and BNP levels in AF ablation patients   Greater improvement in LVEF, better exercise performance, lower BNP, and improved QoL AF ablation patients   Less unplanned hospitalization, lower mortality, greater improvement of LVEF, 6MWT distance, and QoL (MLHFQ) in AF ablation patients   Greater improvement of LVEF at 6 months in AF ablation patients                 Less mortality and HF hospitalizations in AF ablation patients

Number of randomized patients.

6-Min walk distance and serum brain natriuretic peptide did not support the presence of heart failure in all patients. 6MWT, six minute walking test; AF, atrial fibrillation; BNP, brain natriuretic peptide; CRT, cardiac resynchronization therapy device; ICD, implantable defibrillator; LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MRI, magnetic resonance imaging; NYHA class, New York Heart Association functional class; QOL, quality of life; RV, right ventricle.

Rhythm control therapy and stroke
=================================

The clear association of AF and ischaemic stroke may suggest that maintaining sinus rhythm can help to prevent strokes. There is no signal for reduced strokes in the earlier 'rate vs. rhythm' studies (*Table [1](#ehz782-T1){ref-type="table"}*), including the reasonably large AF-CHF trial.[@ehz782-B23] There were only three and seven disabling strokes in each arm in CABANA, without differences between groups.[@ehz782-B9] Interestingly, in a *post hoc* analysis of the ATHENA trial (*Table [1](#ehz782-T1){ref-type="table"}*), patients randomized to dronedarone had a lower risk of stroke or transient ischaemic attack (1.2% vs. 1.8%).[@ehz782-B26] A retrospective, propensity-score matched analysis of a subset of AF patients taken from the Swedish patient registry also suggested that AF ablation may be associated with a lower incidence of ischaemic stroke.[@ehz782-B63] This is similar to propensity-matched patient comparisons in the largest health maintenance organization in Israel, comparing 969 AF patients undergoing AF ablation to 3772 AF controls.[@ehz782-B64] These analyses are prone to several biases, including known, unmeasured and unknown confounders, and others.[@ehz782-B63]

Rhythm control therapy and cognitive decline
============================================

Atrial fibrillation is associated with cognitive dysfunction and dementia. Anticoagulation appears to reduce dementia in patients with AF in a nationwide cohort analysis.[@ehz782-B65] While it is unlikely that antiarrhythmic drug therapy causes cerebral complications (stroke, transient ischaemic attack, or cognitive decline), there is a peri-procedural risk of ischaemic stroke (0.3--1%) as well as a risk of magnetic resonance imaging (MRI)-detected clinically silent ischaemic brain lesions in patients undergoing AF ablation.[@ehz782-B37] This can increase brain damage and subsequently lead to cognitive decline.[@ehz782-B37] Interestingly, the AXAFA--AFNET 5 study found small MRI-detected brain lesions in ca. 30% of patients undergoing a first AF ablation on continuous anticoagulation, but also detected an improved cognitive function as assessed by Montreal Cognitive Assessment (MoCA) 3 months after AF ablation.[@ehz782-B38]

Rhythm control therapy may reduce AF-related stroke risk by reducing AF burden and subsequent improvement in atrial cardiomyopathy,[@ehz782-B66] potentially reducing silent embolic lesions, and possibly improving perfusion and metabolism of the brain. A large retrospective observational study found a lower rate of new-onset dementia in 4212 patients undergoing AF ablation compared to 16 848 non-ablated AF patients, while a substudy in the randomized AFFIRM trial did not find a difference in cognitive function between patients randomized to rate or rhythm control therapy, while the AXAFA study found improved cognitive function in 674 patients 3 months after AF ablation compared to baseline.[@ehz782-B38] The possible cognitive benefits of restoring sinus rhythm in AF patients can be attenuated by atrial cardiomyopathy and by concomitant cardiovascular conditions and other unknown confounders that can cause brain damage, stroke, and cognitive dysfunction in the absence of AF.[@ehz782-B66]^,^[@ehz782-B67] Unfortunately, neither CABANA nor CASTLE-AF reported cognitive function outcomes. Ongoing research such as the case--control DIAL-F cohort (NCT01816308) and the randomized EAST-AFNET 4 trial[@ehz782-B68] will provide further information on the impact of rhythm control therapy including AF ablation on cognitive function.

Rhythm control therapy and atrial cardiomyopathy
================================================

The term 'atrial cardiomyopathy' summarizes the structural, architectural, contractile, or electrophysiological changes in diseased atria.[@ehz782-B66] Cardiovascular diseases (e.g. hypertension, heart failure, valvular heart disease, ischaemic heart disease, or diabetes) but also ageing can contribute to an atrial cardiomyopathy. Atrial fibrillation itself accelerates the underlying disease processes, thus contributing to atrial cardiomyopathy.[@ehz782-B69] Left atrial enlargement, a summative clinical proxy for atrial cardiomyopathy, is partially reversed after AF ablation.[@ehz782-B7]^,^[@ehz782-B70]^,^[@ehz782-B71] Early rhythm control therapy, including AF ablation, has been suggested to slow these processes, thereby simplifying rhythm control therapy and potentially improving long-term outcomes.[@ehz782-B68] Hence, early rhythm control therapy could slow atrial cardiomyopathy. However, this hypothesis requires confirmation in further studies and trials.

Summary and conclusions
=======================

Recent randomized trials and observational data sets including CASTLE-AF and CABANA provide important reassurance on the safety of rhythm control therapy in contemporary patients with AF, including in elderly patients with concomitant cardiovascular diseases. The data confirm the superior effectiveness of AF ablation compared to antiarrhythmic drugs to restore and maintain sinus rhythm, and demonstrate that antiarrhythmic drugs remain effective after AF ablation. Several smaller studies suggest that AF ablation can improve left ventricular function assessed by echocardiography in selected patients with AF and heart failure. Further studies to investigate the impact of rhythm control therapy on LV function in different, clearly defined subsets of patients with AF are warranted. The effects of rhythm control therapy on cardiovascular death, stroke, heart failure, acute coronary syndromes, as well as secondary outcomes such as left atrial, ventricular, and cognitive function require further research, such as the on-going EAST--AFNET 4 trial.[@ehz782-B68]
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